Preclinical proof in print for BAY 1905254
HOLON, Israel—Compugen Ltd. recently shared news of the publication of a peer-reviewed paper in Cancer Immunology Research regarding BAY 1905254, which is an immune checkpoint inhibitor of the immunoglobulin-like domain containing receptor 2 (ILDR2). The preclinical studies and the paper were collaborative efforts between Compugen and Bayer AG. In preclinical studies, BAY 1905254 demonstrated T cell activation in vitro and antitumor activity in vivo. Compugen discovered ILDR2 computationally as a therapeutic target and licensed it to Bayer under a research and development collaboration and license agreement. Bayer is currently evaluating BAY 1905254 in a Phase 1 study in patients with advanced solid tumors, both as a monotherapy and in combination with Keytruda.
"Bayer has been an excellent partner to us and we are very pleased with their continued commitment and investment in the clinical development of BAY 1905254," stated Dr. Anat Cohen-Dayag, president and CEO of Compugen.